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ABSTRACT 
Methotrexate (MTX) is an anti-proliferative drug used for treating inflammatory diseases 
including psoriasis. Nevertheless, its use in localized therapy is impeded due to poor 
transdermal penetration.  
We show that MTX coupled with gold-nanoparticles (GNPs) demonstrates superior anti-
inflammatory efficacy compared to MTX-alone in an imiquimod (IMQ)-induced mouse 
model, significantly reducing γδ T cells, CD4+ T cells, and neutrophils. Furthermore, it was 
well tolerated upon systemic and topical administration. In an AGR129 human xenograft 
mouse model, two-week topical treatment with MTX-GNPs inhibited skin hyperplasia 
significantly better than topical calcipotriol-betamethasone (TCB) and led to profound tissue 
remodeling, involving upregulation of extracellular matrix reorganization and 
downregulation of cornification and keratinization processes. The number of resident T cells 
in the grafts as well as IL-17 production drastically decreased upon MTX-GNP treatment. 
While both MTX and MTX-GNPs directly prevented proliferation and induced apoptosis of 
T cells, suppression of cytokine production was a sh red mechanism of GNP and MTX-
GNPs. 
In conclusion, MTX-GNPs influence immune and stromal components of the skin, leading to 
potent inhibition of pathogenesis in preclinical psoriasis. MTX-GNPs surpass the efficacy of 
conventional MTX and standard of care, emerging as a non-steroidal, topical alternative for 
psoriasis treatment.  
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INTRODUCTION 
Psoriasis is an autoimmune skin disease in which stromal and immune cells, particularly 
resident and circulating T cells, plasmacytoid dendritic cells (pDCs) and neutrophils, play a 
significant role in its pathogenesis (Nestle et al., 2009). Targeted biologicals, such as 
interleukin (IL)-17 blockers, have revolutionized systemic treatment options, but these 
biologicals are only indicated for moderate-to-sever  cases (Kolios et al., 2016). Standard 
care for mild psoriasis includes topical corticosteroids or topical calcipotriol and 
betamethasone (TCB) combinations, the former carrying the risk of long-term side effects, 
including skin atrophy (Samarasekera et al., 2013). 
Methotrexate (MTX) is a folate antagonist used as a systemic treatment of psoriasis 
along with several other inflammatory diseases (Chan and Cronstein, 2002). MTX inhibits 
cell proliferation, and indirectly leads to intracellular adenosine accumulation, which 
subsequently impairs activation and migration of leukocytes such as T cells, macrophages, 
and neutrophils (Chan and Cronstein, 2010). Althoug there is relative tolerability at standard 
dose (15mg weekly), adverse reactions may include hepatotoxicity, myelosuppression, 
infection, and gastrointestinal discomfort (Nast et al., 2017). Localized administration can 
eliminate systemic side effects; however, to date a topical formulation is not yet 
commercially available due to the poor skin penetration of MTX (Avasatthi et al., 2016).  
Gold nanoparticles (GNPs) facilitate drug delivery across biological barriers and 
possess immunomodulatory capacities based on their siz  and surface chemistry (de Araujo 
et al., 2017). Macrophages and other phagocytic cells take up small sized GNPs which are 
shown to impair production of proinflammatory cytokines, for example tumor necrosis factor 
(TNF)-α and IL-6 (Shukla et al., 2005, Tsai et al., 2012). Hence, coupling with GNPs can 
add an immunomodulatory function to the conjugated drug.  
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Coupling of MTX to GNPs (MTX-GNPs) was reported to facilitate effective 
penetration through the human skin barrier in an ex vivo system (Bessar et al., 2016). 
Recently, topical administration of MTX-GNPs was shown to mitigate psoriatic skin 
inflammation, accompanied by a decrease in proliferation and CD8+ T cell numbers, in a 
murine model (Fratoddi et al., 2019). However, the eff ct of MTX-GNPs on immune cells 
and human skin, as well as the detailed mechanism behind remains unknown.  
Here we provide a comprehensive characterization of the anti-inflammatory effect of 
MTX-GNPs in two pre-clinical models of psoriasis. Using a fully murine and a human 
xenotransplant model, we account for the biological differences in mouse and human skin. 
We demonstrate that MTX-GNPs inhibit cell proliferation, cytokine production, and tissue 
fibrosis, leading to restoration of skin immune-homeostasis.  
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RESULTS 
Systemic MTX-GNPs are efficacious and well tolerated in the Imiquimod (IMQ) model. 
IMQ, the active ingredient of ALDARA® cream, is a Toll-like receptor 7 agonist that upon 
topical administration induces strong psoriasis-like inflammation (van der Fits et al., 2009). 
Pathogenesis of this model involves neutrophils, dendritic cells (DCs) and γδ T cells, as well 
as αβ T cells at later stages (Terhorst et al., 2015). In our three-day application setup, 
shortened and optimized to reduce toxicity, ear skin demonstrates histological features of 
psoriasis (Supplementary Figure S1a-d). Inflammation is characterized by skin infiltrating 
CD45+ immune cells, including CD3+ cells and CD11b+ innate immune cells (Supplementary 
Figure S1e and f). Immune cells in the spleen were primarily unaffected, establishing that the 
inflammatory phenotype is confined locally (Supplementary Figure S1g and h). 
Initially, we evaluated the potency of conventional systemic MTX therapy to resolve 
IMQ-induced inflammation (Figure 1a). We observed that daily subcutaneous administration 
was insufficient to diminish ear thickening at tolerable doses of 1mg/kg and 2mg/kg body 
weight (Figure 1b). With high-dose MTX (5mg/kg daily), ear thickness decreased 
significantly, however this regimen led to serious toxicity, which was presented as lethargy 
and severe weight loss (Figure 1b-d). Therefore, inhib tion of local inflammation with 
systemic MTX administration proved intolerable at effective doses. 
To enhance in vivo efficacy of tolerated MTX doses, MTX was coupled with GNPs 
(MTX-GNPs). We administered MTX subcutaneously at the olerable dose of 2mg/kg to 
avoid toxicity-related complications. MTX-GNPs (2mg/k  MTX, 5.5mg/kg Au) significantly 
decreased the inflammation-induced ear thickening and immune infiltration (Figure 2e and f). 
Animals receiving systemic GNPs alone (5.5mg/kg Au)also displayed an improvement of 
ear inflammation, although the effect was significantly less as compared to MTX-GNPs 
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(Figure 2e). Systemic MTX-GNPs were well tolerated without causing obvious signs of 
toxicity, such as lethargy, apathy, severe weight loss, or elevation of serum alanine 
transaminases (ALT) (Supplementary Figure S2a and b). 
 
Topical MTX-GNPs significantly reduces IMQ-induced inflammation. Topical gel 
formulations of MTX, GNPs, and MTX-GNPs were generat d using the Carbopol 980 
carrier. To account for limited drug permeability, selected dosage was six times higher than 
the systemic administration (Figure 2a). Topical MTX lacked efficacy despite the high dose, 
whereas ear inflammation subsided significantly upon t pical MTX-GNPs (p=0.0001, on 
days 5-7) (Figure 2b). Topical GNPs alone also ameliorated inflammation, however, to a 
significantly lower extent than topical MTX-GNPs (Figure 2b). 
Weight loss and serum ALT levels were comparable among all groups and creatinine 
levels were below detection limit for all of the test d topical formulation groups 
(Supplementary Figure S2c and d). Nuclear magnetic r sonance (NMR) did not show any 
traces of MTX, GNP, or MTX-GNPs in the serum of any topical treatment group 
(Supplementary Figure S3). j 
Ear skin treated with MTX or GNPs displayed histological features of IMQ-induced 
psoriatic phenotype, while the MTX-GNP-treated skin appeared uninflamed, mirroring the 
untreated condition (Figure 2c). Immunofluorescence staining of skin suggested both the 
number of infiltrating CD45+ immune cells and IL-17 levels were reduced following MTX-
GNP treatment (Figure 2d).  
 
Topical MTX-GNPs strongly suppress key pathogenic immune cells and restore 
immunological homeostasis. We then characterized the influence of MTX-GNP treatment 
on skin immune cells, using flow cytometry. Compared to the IMQ group, absolute numbers 
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of CD45+ leukocytes significantly decreased upon MTX-GNP trea ment, mirroring the state 
in untreated ears (Figure 3a and b). In the myeloid c mpartment, we observed a pronounced 
effect on CD11b+cells, namely Ly6G+ neutrophils (Figure 3c and d). Regarding the adaptive 
compartment, CD3+ T cells in the ears, including γδ and CD4 T cell subsets were highly 
reduced, while the numbers of CD8+ T cells appeared less responsive at this stage of IMQ-
induced inflammation (Figure 3e-g). Neither MTX nor GNPs alone significantly decreased 
the overall immune cell infiltrate. Only CD11b+ Ly6G+ neutrophils were lower in all 
treatment groups compared to IMQ alone, with the highest significance for MTX-GNPs 
(Figure 3d). Absolute numbers of the aforementioned immune cell populations in the spleen 
remained unaffected by topical therapy (Supplementary Figure S4).  
Proliferation of relevant T cell subsets in the ears was assessed by Ki67 positivity. In all 
experimental groups, γδ T cell proliferation was comparable to the untreated mice, which 
could be explained by earlier activation kinetics of γδ T cells (Figure 3h). Conversely, CD4+ 
and CD8+ T cells showed increased proliferative capacity upon IMQ (Figure 3i and j). MTX-
GNP treatment significantly decreased the percentag of proliferating CD4+ T cells, while its 
effect on CD8+ T cells was limited in this setup.  
 
MTX-GNPs inhibit development of psoriasiform lesion in the AGR human xenograft 
model. The human xenotransplant model is a spontaneous long-term psoriasis model 
generated by grafting symptomless skin (PN) from a psoriasis patient onto AGR mice, a 
triple knock-out strain of type I (A) and type II (G) interferon receptors as well as 
recombination activating gene 2 (R). Transplanted skin develops psoriasis-like phenotype 
within 4 to 8 weeks, through a pathogenic mechanism mediated by skin-resident human 
CD3+ T cells within the graft (Boyman et al., 2004, Di Meglio et al., 2016).  
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Using the AGR model, we assessed the efficiency of MTX-GNPs to resolve human psoriasis 
in comparison to the standard of care topical bethamethasone calcipotriol (TCB) (Figure 4a).  
Vaseline-treated grafts displayed histological features of psoriasis on day 35 (Figure 4b, left). 
The 2-week topical treatment with MTX-GNPs beginning on day 21 significantly reduced 
acanthosis and papillomatosis scores, whereas TCB treatment showed limited efficacy 
(Figure 4b and c). While the inflammation in the Vaseline group heightened between day 21 
and 35, daily topical administration of MTX-GNP in this time frame arrested further disease 
progression, to a higher extent than TCB (Supplementary Figure S5d-e).   
In the Vaseline treatment group, we observed higher number of CD45+ immune cells, mostly 
localized in the dermis (Figure 4d and e). This was primarily composed of CD8+ T cells, 
CD3+ CD8- Forkhead box P3 (Foxp3)+ regulatory T cells (Tregs), and CD3+ CD8- Foxp3- T 
cells (corresponding to conventional CD4 T cells) (Figure 4f and g), similar to lesional 
psoriatic (PP) skin biopsies (Supplementary Figure S5a-c). IL-17 was detected in the 
epidermis and dermis, mostly localized intracellularly, not only in CD45+ immune cells but 
also in CD45- non-immune cells. In the TCB or MTX-GNP-treated skin grafts, the cellular 
infiltrate including IL-17-producing immune cells was significantly reduced or absent (Figure 
4d-g). In conclusion, the development of psoriasis nd activity of pathogenic immune cells in 
the grafted human skin was efficaciously blocked by topical MTX-GNP treatment.  
 
MTX-GNPs directly inhibit T cell proliferation and cytokine production. 
Further, we evaluated if the anti-inflammatory effect observed upon MTX-GNP treatment in 
the AGR model is a result of direct suppression of immune cells or an indirect consequence 
of stromal inhibition. Upon TCR stimulation, human T cells isolated from peripheral blood 
mononuclear cells (PBMCs) demonstrated increased proliferation and decreased apoptosis, as 
expected (Figure 5a-c). MTX alone and MTX-GNPs both inhibited proliferation while GNPs 
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did not have an effect (Figure 5a and b).  In line with this, the percentage of apoptotic cells 
increased upon MTX and MTX-GNPs (Figure 5c). TCR stimulation additionally led to 
elevated cytokine levels in the culture supernatants. Specifically, Th1 cytokine IFN-γ and 
Th17 cytokine IL-17A produced significantly higher upon stimulation, while levels of Th2 
cytokine IL-4 and Treg cytokine IL-10 remained comparable to unstimulated condition 
(Figure 5d). MTX alone did not influence cytokine lvels in the culture supernatants 
however, exposure to GNP or MTX-GNPs lowered IFN-γ and, more significantly IL-17A 
levels. 
 
RNA sequencing reveals significant tissue remodeling in human skin upon topical 
MTX-GNP application. To identify underlying stromal mechanisms of disease modulation, 
we performed RNA sequencing (RNA-seq) of PP and PN skin biopsies and AGR skin grafts. 
RNA-seq revealed 2894 differentially expressed genes (DEGs) and various enriched 
processes, including cell proliferation, keratinization and immune activation, between the PP 
and PN biopsies (Supplementary Figure S6a). As expected, chemokines and cytokines 
implicated in psoriasis pathogenesis (IL-12B, IL-23A, IL17A, IL-1β, IL-36A, CXCL1, and 
CXCL8) were significantly upregulated in PP skin (Supplementary Figure S6b). 
Regarding the AGR grafts, we first performed unbiased Gene Orthology (GO) pathway 
analysis to reveal treatment-specific effects on biological processes. Within the TCB specific 
pathways, upregulation of innate and inflammatory responses as well as downregulation of 
keratinocyte differentiation were the most prominent (Figure 6a). On the other hand, upon 
MTX-GNPs, pathways related to tissue remodeling andwound healing were upregulated, 
while cell proliferation processes were downregulated (Figure 6b). Positive regulation of cell 
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migration and downregulation of keratinization and cornification were the pathways enriched 
upon both therapies (Figure 6a and b).      
We have compared TCB and MTX-GNP treatment to Vaseline-treated controls 
concerning expression levels of major psoriasis-related cytokines. As expected, treated skin 
expressed lower levels of pro-inflammatory signals such as S100A8, S1009, IL1B, IL36G, 
compared to Vaseline control (Figure 6c, highlighted). The effect of TCB treatment on 
immune-related gene expression was stronger compared to MTX-GNP. However, we have 
observed a downregulation of TNF, a major driver of psoriatic inflammation, only upon 
topical MTX-GNP treatment. IL-17A transcript was detectable in the PP skin from the donor 
patients, however, were below detection limit in PNskin post-transplantation. Therefore, we 
assessed the expression of these cytokine genes in the post-transplantation skin using real 
time quantitative PCR (RT-PCR) (Supplementary Figure S6f) and focused our RNA-seq 
analysis to stromal derived gene expression.  
In particular, three gene groups were differentially expressed upon MTX-GNP 
treatment; keratins, histones and matrix proteases (Figure 6d and e).  Keratins were 
downregulated by both of the treatments, as shown by GO analysis, which explains the 
curbed epidermal hyperplasia observed in histology (Figure 4b). Histone gene expression was 
solely decreased in MTX-GNP treated skin. Expression of several matrix proteases was 
upregulated by both treatments but more significantly i  MTX-GNP treatment arm. Overall, 
the trend of gene expression changes between Vaseline and MTX-GNP reflected the trend 
between PP and PN skin (Figure 6e).    
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DISCUSSION  
Here, using in vivo murine psoriasis-like and human xenograft models, we
characterized the therapeutic effect of a topical GNP-coupled MTX formulation, which 
efficiently mitigates psoriasis development and restores local immune homeostasis. MTX-
GNPs reduce proliferation and keratinocyte differentiation and directly act on immune cells 
by blocking T cell proliferation, promoting apoptosis, and diminishing Th1 and Th17 
cytokine production.  
In the fully murine IMQ-model, infiltration of both CD11b-expressing innate cells and 
T cells were reduced upon MTX-GNP treatment with the most prominent effect on the 
neutrophils, γδ T cells and CD4 T cells. This was accompanied by significant decrease in ear 
thickness. Importantly, upon both systemic and topical administration, MTX-GNPs were well 
tolerated at the effective doses.  
Although the IMQ-model is quick and involves key effector cells of psoriasis 
pathogenesis, it has limited translational potential in drug assessment studies, due to vast 
anatomical and immunological difference between mouse and human skin (Hawkes et al., 
2017). Murine skin bears thinner interfollicular epidermis and more hair follicles (Pasparakis 
et al., 2014), which are crucial determinants of skin composition, such as immune privilege 
and drug entry sites (Kabashima et al., 2019). Therefore, our xenograft AGR model is more 
suitable to assess therapeutic efficacy in human psoriatic skin. We demonstrated that psoriatic 
skin grafts in the AGR model harbored tissue-resident T cell subsets including CD4, CD8 and 
and regulatory T cells, akin to lesional psoriasis biopsies from patients (PP), underlining the 
validity of this model for psoriasis research (Boyman et al., 2004, Raeber et al., 2018). A 
two-week topical MTX-GNP treatment of the human skin grafts prevented the development 
of psoriatic phenotype and the therapeutic effect was comparable to systemic treatment with 
anti-TNF-α biologicals, as previously published by our group (Bouchaud et al., 2013, 
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Boyman et al., 2004). We have shown that 14-day topical treatment with MTX-GNP inhibits 
psoriasis development in the AGR xenograft model. To our knowledge, no other treatment 
modality, topical or systemic, has been administered or shown to be effective in a therapeutic 
setting in this xenotransplantation model. After MTX-GNP treatment, the skin was 
histologically similar to healthy-appearing non-lesional biopsies (PN) from patients. We 
demonstrated that the number of above-mentioned immune cells as well as IL-17 levels were 
significantly reduced compared to psoriatic grafts in the Vaseline control group. RT-PCR 
analysis of Il17a mRNA revealed a similar trend for the transcriptional regulation of IL-17 
upon MTX-GNP treatment, which overall suggested an immunomodulatory activity.  
Addressing this hypothesis, we used in vitro assays and proved that MTX-GNPs 
directly act on immune cells. In the presence of MTX-GNPs, TCR-stimulated T cells 
displayed reduced proliferation, impaired cytokine production, and increased apoptosis. 
While MTX alone also exhibited anti-proliferative and pro-apoptotic effects on T cells, GNPs 
did not influence cell survival or proliferation, but lowered cytokine production, most 
significantly IL-17. This indicates that GNPs not only facilitate drug delivery but also 
enhance anti-inflammatory properties. Our in vitro data provides a mechanistic explanation to 
the in vivo effect of GNPs on the IMQ-induced inflammation as well as reduced mRNA and 
protein levels of IL-17 in the AGR model.  
Immune pathology in the human xenograft model was effectively suppressed upon both 
the TCB and MTX-GNP therapy, while MTX-GNP treated grafts had a significantly lower 
histopathological disease score. A major function of MTX is to interfere with proliferation of 
keratinocytes (Weinstein et al., 1990), therefore we hypothesized that suppression of stromal 
cells can be an important mechanism to explain the diff rence between the efficacy of the 
two treatments. In line with this, we demonstrated hat MTX-GNPs induced a strong 
downregulation of anabolic and proliferative processes in skin grafts, while TCB did not. 
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Additionally, we discovered that topical MTX-GNPs increase the expression of genes 
involved in extracellular matrix (ECM) breakdown and reorganization, including members of 
matrix metalloprotease (MMP), a disintegrin and metalloproteinase (ADAM), a disintegrin 
and metalloproteinase with thrombospondin motifs (ADAMTS) family proteases. It is well-
established that ECM buildup and crosstalk with T cells during inflammation can enhance 
pathogenesis, impede resolution, and foster fibrosis development (Bonnans et al., 2014, 
Kaisho and Akira, 2003, McFadden et al., 2012, Tsan and Gao, 2004). In the same context, 
matrix proteases can limit inflammation and tissue fibrosis via ECM degradation. We 
propose that the enhanced ECM breakdown upon MTX-GNP treatment in the AGR model 
serves as an additional mechanism to resolve inflamm tion. In line with this, several in vivo 
studies with diabetic mouse and liver injury rat models have shown that GNPs support wound 
healing and inhibit fibrosis (Chen et al., 2012, de Carvalho et al., 2018), which provides a 
possible explanation to tissue-remodeling function of MTX-GNPs. Overall, the therapeutic 
potency of MTX-GNPs with its multifactorial mode ofaction exceeds TCB, the standard of 
care, and MTX in the studied models. Identification of exact mechanisms, both 
immunomodulatory and stromal, needs further investigation, including clinical assessments. 
In conclusion, MTX-GNPs can potentially extend medical practice for the non-steroidal 
topical treatment of psoriasis and various inflammatory skin disorders, such as hidradenitis 
suppurativa, neutrophil-mediated autoimmune and allergic dermatoses as well as tissue 
remodeling dysfunctions and keloid formations. 
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MATERIAL AND METHODS 
Animals: C57BL/6 female mice purchased from Charles River Laboratories and AGR129 
mice were bred in house homozygously (Boyman et al., 2004). Animals were maintained 
under specific pathogen-free conditions and all experiments were performed with 8-12-week-
old male or female mice.  
Compounds: Systemic and topical formulations for MTX, GNPs and MTX-GNPs as well as 
the carrier Carbopol 980 were provided by Midatech Pharma, Abingdon, United Kingdom.  
In vivo Imiquimod (IMQ) model: Ear inflammation was induced by daily application of 60-
70mg ALDARA® (5% IMQ, MEDA Pharma, Switzerland) for three consecutive days. 
Animal wellbeing was evaluated daily with weight measurement by an electronic scale. Daily 
ear thickness measurements were recorded using a diit l micrometer (Mitutoyo®, Japan). 
Systemic therapies were administered as subcutaneous injections (200µl) and topical 
therapies as 75µl gel per ear at doses indicated in the figures. After 7 consecutive days of 
treatments, serum was collected for creatinine and alanine transaminase (ALT) 
measurements. 
AGR model: Keratome biopsies of PN were obtained from consenting patients and were 
transplanted onto the back of AGR129 mice, as previously described (Boyman et al., 2004). 
Vaseline (Unilever, US), topical calcipotriol 0.05mg/g and betamethasone dipropionate 
0.5mg/g (TCB, Daivobet® gel, Leo Pharma, Denmark), or MTX-GNP gel was topically 
applied daily onto the grafts from day 21 post-transplantation until termination on day 35. 
Grafted skin was harvested for histological evaluation and RNA sequencing. 
In vitro T cell stimulation: PBMCs from 5 healthy donors were isolated via Ficoll gradient. 
CD3+ cells were positively selected using Pan T cell Iso ation Kit (Miltenyi Biotec Swiss 
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AG, Switzerland) according to manufacturer’s instruc ions. Isolated T cells were labeled with 
CellTrace Violet (ThermoFisher Scientific, USA) at 370C for 20 minutes. T cells were 
stimulated for 4 days with anti-CD3 and anti-CD28 antibodies, coated on 96 well Flat bottom 
plates, in the absence or presence of 100µM of MTX, MTX-GNPs, or GNPs with equivalent 
MTX or Au concentration. After stimulation, cytokine levels in the supernatants were 
measured by FACS using Legendplex Human Th Cytokine Panel (Biolegend UK Ltd, United 
Kingdom) according to manufacturer’s instructions. Proliferation and apoptosis assessment 
of cells were performed by FACS.  
FACS: Mouse ears were digested to obtain single cell suspensions (Bouchaud et al., 2013). 
Single cell suspensions of mouse ears, spleens, or i olated T cells were stained in phosphate 
buffered saline containing 1% FCS and 2mM EDTA. Forthe intranuclear staining, cells were 
fixed and permeabilized after surface staining, according to manufacturer’s instructions using 
the Foxp3/ Transcription Factor Staining kit (eBioscience, ThermoFisher Scientific, USA). 
For the assessment of apoptosis Fixable Viability De eFluorTM 780 (eBioscience, 
ThermoFisher Scientific, USA, Catalog No: 65-0865-14) was added to the staining mixture 
of fluorescence-conjugated antibodies. Detailed list of antibodies and providers can be found 
in the supplementary materials (Table S1).  
Histology, Confocal Laser Scanning Microscopy (CLSM): Mouse ears or human skin 
grafts were embedded in Optimal Cutting Temperature compound (TissueTek, Sakura 
Finetec, USA) and stored at -800C until use. 7µm sections were air dried, fixed with 4% 
Paraformaldehyde, and stained with H&E based on standard protocols. For 
immunofluorescence staining, PFA-fixed sections were blocked with PBS containing 5% 
BSA, 0.1% Triton X prior to antibody staining. Mouse and human skin were stained with 
primary conjugated or unconjugated antibodies. AlexaFluor647 or AlexaFluor594 conjugated 
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anti-rabbit antibodies were used as the secondary antibody. Images were acquired on Leica 
SP8 STED Inverse 3X CLSM, using HC PL APO CS2 20X immersion or 63X oil objectives. 
Detailed list of antibodies and providers can be found in the supplementary materials (Table 
S2). 
Histology, CLSM quantifications: In human skin samples 10 representative histological 
fields were selected for the quantification of acanthosis and papillomatosis index (Bouchaud 
et al., 2013, Fraki et al., 1983). In the AGR xenotransplantation experiments CD3, CD8, 
CD3+CD8-Foxp3+, CD3+CD8-Foxp3-, CD45+, and CD45+IL17+ cells were independently 
quantified by two blinded investigators. For each quantified population, 12-16 images of 
whole graft skin were selected.  
RNA sequencing and data analysis: Total RNA was isolated from human punch biopsies, 
and AGR skin grafts with RNeasy Fibrous Tissue Mini Kit (QIAGEN, Germany). The 
quality and quantity of RNA was assessed by Tape Station. Library was prepared with 
SMARTer Stranded Total RNA-Seq Kit - Pico Mammalian Kit (Clontech, USA) and 
sequenced on a NovaSeq S1 Flowcell in single end 101bp mode. Adapters and low-quality 
tails were trimmed from reads prior to read alignmet. STAR aligner (v2.6.1c) (Dobin et al., 
2013) was used to align the RNA-seq dataset to Ensembl genome build GRCh38.p10 
(Release 91). Gene expression counts were calculated wi h feature counts from Bioconductor 
package Rsubread (v1.32.1) (Liao et al., 2013). A gene was considered expressed if, in at 
least one comparison group, it had more than 10 counts in more than half of the samples. 
Differential expressed genes were detected using Bioconductior package DESeq2 (v1.22.1) 
(Aad et al., 2014). Genes with p-value ≤ 0.01 and log2 fold change ≥ 0.5 were considered 
significant in this study. Overrepresentation analysis of Gene Ontology categories was 
performed using Bioconductor package clusterprofiler (v3.10.1).  
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For Heatmap analysis, mean normalized counts of each group was normalized against the 
mean normalized counts of the Vaseline control group. The relative expression levels 
obtained from normalization is expressed as log2. For the floating bar plots, normalized 
counts of each sample from different groups are shown in log2 scale. 
Statistics: Mice were randomly assigned to experimental groups, and results are shown as 
mean ± SD, or group means, as stated. Comparison of two groups were done by unpaired, 
parametric two-tailed Student’s t test. If multiple groups were statistically compared, 
unpaired One Way Anova or Two-Way Anova was performed, as reported, followed by 
Tukey’s multiple comparison test. RNA-sequencing data was analyzed using Bioconductior 
package DESeq2 (Aad et al., 2014).  
Study approval: All animal experimentations were approved by the Cantonal Veterinary 
Office (ZH187/16) and performed in accordance with the Swiss Animal Laws. Ethical 
approval for human samples (skin grafts, biopsies, and blood) was obtained by the Cantonal 
Ethics Committee Zurich (2018-01413) and performed in accordance. All patients has given 
written, informed consent before their participation n the study.  
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FIGURE LEGENDS 
 
Figure 1. Efficacy of systemic MTX and MTX-GNP in the IMQ model. (a) Experimental scheme.  
(b) Left, representative plot of two independent experim nts depicting ear thickness of untreated (n = 
4), IMQ-treated (n = 5), and systemic MTX-therapy (n = 4 for 1mg/kg, 2mg/kg, 5mg/kg) receiving 
animals. Right, corresponding statistical analysis. (c and d) Weight changes of different treatment 
groups in the MTX dose escalation (n = 4-5) calculated as % weight change from pretreatment weight 
and recorded daily (c) and plotted for day 7 (d). (e) Left, ear thickness of untreated (n = 8), IMQ-
treated (n = 9), and systemic therapy (n = 12 for MTX, n = 8 for GNP, and n = 7 for MTX-GNP) 
receiving animals. Right, corresponding statistical analysis. (f) Quantification of CD45+ (c), CD3+ (d) 
and CD11b+ (e) cell populations in the ears of untreated (n = 10-1 ), IMQ-treated (n = 11), and 
systemic MTX (n = 7-9), GNP (n = 4-7), or MTX-GNP (n = 4-6) therapy receiving animals on day 7. 
Data are pooled from 4 (b-d) or 3 (e and f) independent experiments and shown as mean ± SD (b-e) 
or mean (f). Data are analyzed by either One-Way (d and f) or Two-Way Anova (b, c and e). ns = 
non-significant, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
 
Figure 2. Efficacy of topical MTX-GNP in the IMQ model. (a) Experimental scheme. (b) Left, ear 
thickness of untreated (n = 8), IMQ-treated (n = 12), and topical therapy (n = 7 for Carbopol 980 gel 
carrier, n = 8 for MTX gel, n = 9 for GNP, and n = 9 for MTX-GNP) receiving animals. Right, 
corresponding statistical analysis. (c-d) Representative H&E (c) and immunofluorescence (d) staining 
of ear skin harvested on day 7. (c) Scale bar = 200µm. (d) CD45 (red), IL-17 (green), and DAPI 
(blue). Scale bar = 100µm. Data are pooled from 3 independent experiments and shown as mean ± 
SD. Data are analyzed by Two-Way Anova. ns = non-sig ificant, * p<0.05, ** p<0.01, *** p<0.001, 
**** p<0.0001. 
 
Figure 3. Flow cytometry analysis of skin immune landscape upon topical therapies on day 7. 
(a) Representative pseudocolor plots and (b) quantification of CD45+ cell population in ears. (c) 
Quantification of total CD11b+ cell populations and (d) Ly6G+ and Ly6G- cell composition of 
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CD11b+ cells. (e) Quantification of CD3+ cell population and (f) αβ and γδ T cell composition of 
CD3+ T cells. (g) Quantification of CD4+ and CD8+ T cell composition of αβ CD3+ T cells. (h-j) 
Ki67+ cell percentage of  γδ+ (h), CD4+ (i) and CD8+ (j) T cell subsets. Data are pooled from 3 
independent experiments and represented as mean. Data are analyzed by either One-Way (b, c, e and 
h-j) or Two-Way Anova (d, f and g). ns = non-significant.  
 
Figure 4. Effect of topical MTX-GNP on the AGR model of psoriasis. (a) Experimental scheme. 
(b) Representative H&E staining of skin grafts harvested on day 35. Scale bar = 100µm. (c)
Quantification of acanthosis (left) and papillomatosis index (right) upon Vaseline (n = 4), TCB (n = 
5), or MTX-GNP (n = 5) treatments. (d-g) Representative immunofluorescence staining of Vaseline, 
TCB, and MTX-GNP treated transplant skin on day 35.(d) CD45 (green, arrowhead), IL-17 
(magenta, asterisk), and DAPI (blue). (e) Quantification of CD45+ and CD45+IL-17+ cells from the 
immunofluorescence images. (f) CD3 (green, arrowhead), Foxp3 (magenta, asterisk), CD8 (red, 
arrow), and DAPI (blue). (g) Quantification of CD3+, CD3+CD8+, CD3+CD8-Foxp3+ and CD3+CD8-
Foxp3- cells from the immunofluorescence images. Bottom images display the indicated squares in 
higher magnification. Scale bar = 100µm (top), and 50µm (bottom). Data are pooled from 3 
independent experiments and shown as mean. Data are n lyzed by One-Way Anova. ns = non-
significant. 
 
Figure 5. MTX-GNPs directly inhibit T cell proliferation and cytokine production. (a) 
Representative histograms of CTV staining of CD4+ and CD8+ T cells following 4-day culture with 
media or with coated anti-CD3, anti-CD28 stimulation t gether with media, MTX, GNP or MTX-
GNP. (b and c) Percentage of (b) proliferating and (c) apoptotic CD3+, CD4+ and CD8+ T cells at day 
4 upon indicated culture conditions. (d) Concentration of IFN-γ, IL-17A, IL-4 and IL-10 in the 
supernatant of cultured T cells.  
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Figure 6. Transcriptomic profile of the psoriatic skin grafts. (a and b) Enriched biological 
processes upon TCB (a) or MTX-GNP (b) treatment compared to Vaseline. Red bars: upregulation, 
blue bars: downregulation, filled bars: common pathw ys between two therapies. (c and d) DEGs in 
TCB and MTX-GNP treatment normalized to Vaseline (c) immune related genes and () gene sets 
involved in keratin synthesis, histone modification, a d matrix proteases production. (e) Normalized 
expression of selected DEGs from Vaseline, TCB and MTX-GNP treated grafts and, PP and PN skin 
biopsies.  
 






SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure S1. The three-day IMQ model. (a) Experimental scheme. (b) 
Representative H&E staining of untreated (left) andIMQ-treated (right) ear skin on day 7. Scale bar = 
100µm. (c) Top, ear thickness of untreated (n = 8) and IMQ-treated (n = 12) animals. Bottom, 
corresponding statistical analysis. (d) Top, weight changes of untreated (n = 8) or IMQ-trea ed (n = 
12) animals were calculated as % weight change from pretreatment weight and recorded daily. 
Bottom, statistical analysis of weight differences of the two groups between days 3-7. (e-h) CD45+, 
CD3+ and CD11b+ cells in the ears (e and f) and spleen (g and h) of untreated (n = 8-10) and IMQ-
treated (n = 9) animals. CD3+ and CD11b+ cells are pre-gated on CD45+ population. Representative 
pseudocolor plots (e and g) and quantification of populations (f and h). Data are pooled from 4 
independent experiments and shown as mean ± SD (c and d) or mean (f and h). Data are analyzed by 
either Student’s t test (two tailed) (f and h) or Two-Way Anova (c and d). ns = non-significant, * 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
 
Supplementary Figure S2. Toxicity of systemic and topical MTX, MTX-GNP, and GNP 
therapies in the IMQ-model. (a and c) Weight changes of different treatment groups in the (a) 
systemic (n = 8-15) and (c) topical (n = 7-15) MTX-GNP experiments, calculated as % weight change 
from pretreatment weight and recorded daily (left), and plotted for day 7 (right). (b and d) Serum 
alanine transaminase (ALT) levels from the (b) systemic (n = 3-11) and (d) topical (n = 6-11) MTX-
GNP experiments in the IMQ model. Data are pooled from 3 independent experiments and shown as 
mean ± SD (a and c) or mean (b and d). Data are analyzed by One-Way Anova. ns = non-sigificant. 
 
Supplementary Figure S3. 1H NMR analysis of systemic bioavailability of topical therapies in 
the IMQ model. (a and b) 1H NMR (nuclear magnetic resonance) spectra of samples containing 1 
(25 µg/mL, yellow), 10 (250 µg/mL, orange) and 100 doses (2500 µg/mL, blue) of MTX dissolved in 
D2O, in order to determine the sensitivity limit. (a) The insert shows a zoom on the region around 
3.05 ppm that displays a prominent MTX singlet peak. (b) The insert shows a zoom on the baseline to 
display also weak signals. The sensitivity limit for MTX can thus be determined to be 25 µg/ml. (c 
and d) 1H NMR spectra of serum samples from the topical tretm nt experiments of untreated (green), 
MTX-GNP (purple), GNP (yellow), or MTX (orange) treat d animals and a reference measure (blue) 
with 100 doses of MTX (c) or MTX-GNP (d). The asterisk indicates signals stemming for ethanol 
impurities. (c) Both low-field (left) and high-field regions (right) of 1H NMR spectra are displayed. 
Signals marked with the dashed lines indicate characteristic MTX signals. Evidently, no MTX traces 
were detected in the investigated samples (sensitivity limit > 25 µg/mL). (d) The signal marked with 
the dashed line indicates a characteristic MTX-GNP signal, which cannot be detected in any of the 
other samples. 
 
Supplementary Figure S4. Splenic immune landscape in the IMQ model. (a) Representative 
pseudocolor plots depicting the employed gating strategy in order to identify relevant immune subsets 
in the spleens and ears. Displayed plots are of splenocytes from naïve C57BL/6 mice. (b-d) 
Quantification of CD45+ (b), CD3+ (c) and CD11b+ (d) cell populations in the spleens of mice from 
the topical treatment experiments on day 7. Quantifica on of (e) αβ and γδ T cell composition of 
CD3+ T cells, (f) CD4+ and CD8+ T cell composition of αβ CD3+ T cells and (g) Ly6G+ and Ly6G- 
myeloid cell composition of CD11b+ cells. n = 9-13 for untreated, n = 9-11 for IMQ-treated, n = 5-7 
for topical therapy (MTX, GNP, or MTX-GNP) receiving animals. Data are pooled from 3 
independent experiments and shown as mean. Data are an lyzed by either One-Way Anova (b-d) or 
Two-Way Anova (e-g). ns= non-significant.  
 
Supplementary Figure S5. Histological characterization of patient psoriatic (PP) and healthy-
appearing (PN) skin. (a-c) Representative H&E (a) and immunofluorescence staining (b and c) of 
psoriatic (PP) (a left and b) and normal-appearing (PN) (a right and c) skin biopsies taken from a 
psoriasis patient (n = 3). (a) Scale bar = 200µm. (b and c) Left, CD45 (green, arrowhead), IL-17 
(magenta, asterisk), and DAPI (blue). Right, CD3 (green, arrowhead), Foxp3 (magenta, asterisk), 
CD8 (red, arrow), and DAPI (blue). Scale bar = 100µm (top), and 50µm (bottom). (d) Representative 
H&E staining of PN skin (left), skin grafts harvestd on day 21 (middle) and day 35 (right). Scale bar 
= 100µm. (e) Quantification of acanthosis (left) and papillomatosis index (middle) and total T cell 
counts (right) on day 0 (n = 2), day 21 (n = 6) andday 35 upon Vaseline (n = 5-6,  black open circles), 
TCB (n = 5-6, blue open circles), or MTX-GNP (n = 5-6, purple open circles) treatments. Data are 
shown as mean ± SEM.   
 
Supplementary Figure S6. Transcriptomic changes of the psoriatic human skin and graft upon 
TCB and MTX-GNP treatment. (a) Gene expression differences between the PP versus PN skin 
biopsies. (b) Differentially expressed genes (DEGs) between the PP and PN skin biopsies, from the 
selected gene sets of cytokines and chemokines. (c-d) Gene expression differences between the MTX-
GNP versus Vaseline (c) and TCB versus Vaseline (d) treated human skin grafts from the AGR 
experiments. (e) Regulation of known target genes of TCB treatment. (f) RT-PCR evaluation of Il17a 
mRNA expression in the post-transplantation AGR skin from Vaseline, TCB, and MTX-GNP 
treatment groups (n = 2, per treatment group). Data in (f) are analyzed by One-Way Anova. 
 
SUPPLEMENTARY METHODS 
 
 
Quantitative Real-Time PCR (RT-PCR): complementary DNA (cDNA) remaining from 
the RNA sequencing was used for quantitative Real-Time PCR analysis Il17a expression. RT 
PCR was performed as previously published (Bouchaud et al., 2013). Briefly a 3-minute 
denaturation step at 95°C was followed by 40 cycles at 95°C for 5 seconds and 60°C for 30 
seconds. A final dissociation stage was carried out at 95°C for 5 seconds and 60°C for 30 
seconds. Rps29 was used as a house-keeping gene, and the expression of Il17a was 
normalized to the expression of Rps29 within the same sample. Genes of interest were 
amplified using the following primers:  
Rps29 Forward: 5`-CGC TCT TGT CGT GTC TGT TCA-3' 
Rps29 Reverse: 5`-CCT TCG CGT ACT GAC GGA AA-3' 
Il17a Forward: 5`-CAA TCC CAC GAA ATC CAG GAT G-3' 
Il17a Reverse: 5`-GGT GGA GAT TCC AAG GTG AGG-3' 
 
1H NMR: 1H NMR spectra were detected on a 600 MHz (14.1 T) Bruker HDIII NMR 
spectrometer (USA) equipped with a TXI Z-gradient probe operating at 298 K. Sample 
volumes of 250 µL were loaded in Shigemi-type sample tubes as optimized for proton 
detection. All samples either contained 10% v/v D2O (for serum measurements) as lock-
solvent or were dissolved in pure D2O (for MTX titration). Free induction decays were 
recorded by averaging 256 detections with 90˚ pulses, each after a Watergate sequence (Rule 
and Hitchens, 2006) that suppresses the water resonance using a 10 ms long PC9 shaped 
pulse. The carrier frequency was set to 4.7 ppm. Data were processed using NMRpipe 
(Delaglio et al., 1995) and home-written MATLAB scripts. All FIDs were apodized and zero-
filled prior to Fourier transformation. 
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Table S1: Antibodies used for Flow Cytometry: 
Antibody Fluorophore Supplier Clone Catalog No 
anti-mouse CD3 BV510 BD 145-2C11 563024 
anti-mouse CD45.2 FITC invitrogen 1O4 11-0454-82 
anti-mouse CD8b APC-eFluor780 invitrogen H35-17.2 47-0083-82 
anti-mouse CD4 Percp-Cyanine5.5 invitrogen RM4-5 45-0042-82 
anti-mouse Ly6G BV711 Biolegend 1A8 127643 
anti-mouse CD11b BV650 Biolegend M1/70 101239 
anti-mouse Ki67 PE-Cyanine7 invitrogen SolA15 25-5698-80 
anti-mouse γδ TCR eFluor450 invitrogen eBioGL3 48-5711-82 
anti-human CD3 BV785 Biolegend UCHT1 300401 
anti-human CD4 BUV395 BD SK3 563550 
anti-human CD8 BV510 Biolegend RPA-T8 301047 
 
Table S2: Antibodies used for Immunofluorescence: 
Antibody Fluorophore Supplier Clone Catalog No 
anti-mouse CD45.2 AlexaFluor488 Biolegend 1O4 109816 
anti-mouse/human IL-17 unconjugated Abcam polyclonal ab79056 
anti-human CD45 AlexaFluor488 Biolegend 2D1 304019 
anti-human CD3 AlexaFluor488 Biolegend UCHT1 300454 
anti-human CD8 AlexaFluor647 Biolegend SK1 344726 
anti-human Foxp3 eFluor570 invitrogen 236A/E7 41-4777-82 
 






